These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 35053290)

  • 1. Antioxidant Roles of SGLT2 Inhibitors in the Kidney.
    Llorens-Cebrià C; Molina-Van den Bosch M; Vergara A; Jacobs-Cachá C; Soler MJ
    Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis.
    Maeda S; Matsui T; Takeuchi M; Yamagishi S
    Diabetes Metab Res Rev; 2013 Jul; 29(5):406-12. PubMed ID: 23508966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics.
    Packer M
    Am J Kidney Dis; 2021 Feb; 77(2):280-286. PubMed ID: 32711072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-Glucose Co-Transporter 2 Inhibitors Correct Metabolic Maladaptation of Proximal Tubular Epithelial Cells in High-Glucose Conditions.
    Shirakawa K; Sano M
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Mitochondria and Reactive Oxygen Species-Driven Pathogenesis in Diabetic Nephropathy.
    Lindblom R; Higgins G; Coughlan M; de Haan JB
    Rev Diabet Stud; 2015; 12(1-2):134-56. PubMed ID: 26676666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework.
    Packer M
    Diabetes Obes Metab; 2020 May; 22(5):734-742. PubMed ID: 31916329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
    Maki T; Maeno S; Maeda Y; Yamato M; Sonoda N; Ogawa Y; Wakisaka M; Inoguchi T
    Sci Rep; 2019 Mar; 9(1):4703. PubMed ID: 30886225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose cotransporter inhibitors and oxidative stress: An update.
    Yaribeygi H; Atkin SL; Butler AE; Sahebkar A
    J Cell Physiol; 2019 Apr; 234(4):3231-3237. PubMed ID: 30443936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation.
    Ishibashi Y; Matsui T; Yamagishi S
    Horm Metab Res; 2016 Mar; 48(3):191-5. PubMed ID: 26158396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidant Mechanisms in Renal Injury and Disease.
    Ratliff BB; Abdulmahdi W; Pawar R; Wolin MS
    Antioxid Redox Signal; 2016 Jul; 25(3):119-46. PubMed ID: 26906267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of antioxidants in redox regulation of diabetic cardiovascular complications.
    Turan B
    Curr Pharm Biotechnol; 2010 Dec; 11(8):819-36. PubMed ID: 20874678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and Diabetic Kidney Disease: Role of Oxidant Stress and Redox Balance.
    Sharma K
    Antioxid Redox Signal; 2016 Aug; 25(4):208-16. PubMed ID: 26983586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism.
    Layton AT; Vallon V
    Am J Physiol Renal Physiol; 2018 May; 314(5):F969-F984. PubMed ID: 29361669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes and Kidney Disease: Role of Oxidative Stress.
    Jha JC; Banal C; Chow BS; Cooper ME; Jandeleit-Dahm K
    Antioxid Redox Signal; 2016 Oct; 25(12):657-684. PubMed ID: 26906673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease.
    Ravindran S; Munusamy S
    J Cell Physiol; 2022 Feb; 237(2):1182-1205. PubMed ID: 34713897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
    Reyes-Pardo H; Bautista R; Vargas-Robles H; Rios A; Sánchez D; Escalante B
    BMC Nephrol; 2019 Aug; 20(1):292. PubMed ID: 31375080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
    Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
    Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. myo-Inositol Oxygenase Overexpression Accentuates Generation of Reactive Oxygen Species and Exacerbates Cellular Injury following High Glucose Ambience: A NEW MECHANISM RELEVANT TO THE PATHOGENESIS OF DIABETIC NEPHROPATHY.
    Sun L; Dutta RK; Xie P; Kanwar YS
    J Biol Chem; 2016 Mar; 291(11):5688-5707. PubMed ID: 26792859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.